Cytomegalovirus Antibody (DDG9 and CCH2)
Novus Biologicals, part of Bio-Techne | Catalog # NBP1-22532
Key Product Details
Species Reactivity
Cytomegalovirus, Virus
Applications
Immunohistochemistry, Immunohistochemistry-Paraffin
Label
Unconjugated
Antibody Source
Monoclonal Mouse IgG1 Kappa/IgG2a Kappa Clone # DDG9 and CCH2
Concentration
This product is unpurified. The exact concentration of antibody is not quantifiable.
Product Specifications
Immunogen
BALB/C mice were immunized with cytomegalovirus infected cell lysate. This antibody is a cocktail of DDG9 and CCH2.
Localization
Nuclear
Specificity
This cocktail antibody reacts with an immediate early and early CMV antigens. The antibody stains infected cells giving a nuclear staining pattern with an immediate early and an early antigen.
Clonality
Monoclonal
Host
Mouse
Isotype
IgG1 Kappa/IgG2a Kappa
Scientific Data Images for Cytomegalovirus Antibody (DDG9 and CCH2)
Immunohistochemistry-Paraffin: Cytomegalovirus Antibody (DDG9 and CCH2) [NBP1-22532]
Immunohistochemistry-Paraffin: Cytomegalovirus Antibody (DDG9 and CCH2) [NBP1-22532] - IHC analysis of a formalin fixed paraffin embedded tissue section of CMV infected lung using Cytomegalovirus antibody (clone DDG9 and CCH2).Immunohistochemistry: Cytomegalovirus Antibody (DDG9 and CCH2) [NBP1-22532]
Immunohistochemistry: Cytomegalovirus Antibody (DDG9 and CCH2) [NBP1-22532] - Human Placenta CMV. HIER sodium citrate 6.0 - 30 minutes 1:10 dilution. This image was submitted via customer Review.Immunohistochemistry-Paraffin: Cytomegalovirus Antibody (DDG9 and CCH2) [NBP1-22532]
Immunohistochemistry-Paraffin: Cytomegalovirus Antibody (DDG9 and CCH2) [NBP1-22532] - IHC analysis of a formalin fixed paraffin embedded tissue section of CMV infected lung using Cytomegalovirus antibody (clone DDG9 and CCH2).Applications for Cytomegalovirus Antibody (DDG9 and CCH2)
Application
Recommended Usage
Immunohistochemistry
1:10-1:25
Immunohistochemistry-Paraffin
1:10-1:25
Application Notes
IHC-P: recommended pretreatment of citrate buffer, pH 6.0. Recommended incubation time of 30 min at RT.
Reviewed Applications
Read 2 reviews rated 5 using NBP1-22532 in the following applications:
Formulation, Preparation, and Storage
Purification
Tissue culture supernatant
Formulation
Tissue culture supernatant
Preservative
0.05% Sodium Azide
Concentration
This product is unpurified. The exact concentration of antibody is not quantifiable.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C. Do not freeze.
Background: Cytomegalovirus
Cytomegalovirus is a common virus, infecting ~60% of adults in developed countries and over 90% in developing countries, as indicated by presence of specific IgG antibodies (2-4). Although a majority of people infected remain asymptomatic, immunocompromised people, organ transplant recipients, and fetuses and newborns are more susceptible to HCMV-associated diseases (1-4). Annually, up to 2% of newborns are born with HCMV, making it the most common congenital infection (2-4). Cytomegalovirus is known to cause sensorineural hearing loss (SNHL), mental retardation, chorioretinitis, skin lesions, as well as end organ disease (3,5). There are a few CMV therapeutics approved by FDA including valganciclovir and letermovir; however, despite some benefits, there is the need for new antivirals and combination therapies (5). Potential new treatment options include monoclonal antibodies and sirtuins (5).
References
1. Connolly SA, Jardetzky TS, Longnecker R. The structural basis of herpesvirus entry. Nat Rev Microbiol. 2021;19(2):110-121. https://doi.org/10.1038/s41579-020-00448-w
2. Griffiths P, Reeves M. Pathogenesis of human cytomegalovirus in the immunocompromised host. Nat Rev Microbiol. 2021;19(12):759-773. https://doi.org/10.1038/s41579-021-00582-z
3. Krstanovic F, Britt WJ, Jonjic S, Brizic I. Cytomegalovirus Infection and Inflammation in Developing Brain. Viruses. 2021;13(6):1078. Published 2021 Jun 4. https://doi.org/10.3390/v13061078
4. Griffiths P, Baraniak I, Reeves M. The pathogenesis of human cytomegalovirus. J Pathol. 2015;235(2):288-297. https://doi.org/10.1002/path.4437
5. Acosta E, Bowlin T, Brooks J, et al. Advances in the Development of Therapeutics for Cytomegalovirus Infections. J Infect Dis. 2020;221(Suppl 1):S32-S44. https://doi.org/10.1093/infdis/jiz493
Alternate Names
CMV; HHV 5; HHV5; Human herpesvirus 5
Additional Cytomegalovirus Products
Product Documents for Cytomegalovirus Antibody (DDG9 and CCH2)
Product Specific Notices for Cytomegalovirus Antibody (DDG9 and CCH2)
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...